strengthen oncolog busi lead growth
maintain buy rate downgrad target price
deriv tp base estim ep
forward look price-to-earnings give
upsid potenti
apart discuss base estim
number factor keytruda sale recov decent
pace progress lynparza add
strength oncolog busi strong global launch
zepati growth anim busi primarili driven
continu strength companion anim busi includ
bravecto growth rumin busi recent
fda approv keytruda lynparza
metastat lung cancer keytruda remain lead
treatment option across i-o non-i-o therapi fda
approv lynparza use patient germlin brca-
mutat metastat breast cancer
previous treat chemotherapi either
neoadjuv adjuv metastat set
see great opportun lynparza compani
co-develop co-commerci colleagu
approv broader ovarian cancer label
current launch new metastat breast cancer
revenu number littl lower
estim better cost manag beat
adjust ep estim
compani namemerck compani inc new tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispidearavindra except ep crispidea merck compani inc april
incom statement
result
guidanc
non-
per share item
product perform develop
valuat consensu perform
revenu quarter increas
compar pharma revenu
increas compar
total revenu anim health care
quarter increas compar
net loss quarter declin
compar ep
compar non-gaap ep
compar
japanes ministri labor welfar
approv keytruda treatment patient
radic unresect urotheli carcinoma progress
cancer chemotherapi
geograph wise revenu
declin compar
sale increas compar
price-to-earnings drop averag till
averag price-to-earnings average stdev
average stdev price-to-earnings
went averag current
experienc declin sale major
brand keytruda bridion zepati lynparza
gain market share global market
expect low mid-singl digit growth revenu
maintain rate buy tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date feb inform merck compani inc april
incom statement
result
guidanc
non-
per share item
product perform develop
valuat consensu perform
incom statement month end month end month month end month month revenu total- total revenu gross selling/general/admin expens research depreciation/amortization- interest expens incom net operating- unusu expens oper expens total- total oper oper interest incom expens net non-operating- loss sale assets- incom incom minor equiti affiliatesnet incom extra account changediscontinu operationsextraordinari itemnet prefer dividendsincom avail common excl extra incom avail common incl extra basic weight averag sharesbas ep exclud extraordinari itemsbas ep includ extraordinari itemsdilut adjustmentdilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari itemsdividend per share common stock primari gross dividend common stocknet incom stock base comp expensebas ep stock base comp expsensedilut ep stock base comp expensedepreci supplementaltot special itemsnorm incom taxeseffect special item incom taxesincom tax ex impact special itemsnorm incom taxesnorm incom avail commonbas normal epsdilut normal actual annual estim annual actual quarterli merck compani inc april
oper activ compar cash
oper activ compar declin cash provid oper
activ reflect payment relat settlement feder incom tax issu payment
relat format collabor astrazeneca payment made
merck relat settlement world-wide keytruda patent litig
provid invest activ compar
cash invest activ compar chang cash due
lower purchas secur invest higher proce sale secur
invest lower use cash acquisit busi
use financ activ compar cash
financ activ compar increas cash use financ
activ due proce issuanc debt higher purchas treasuri stock
lower proce exercis stock option partial off-set lower payment debt
income/start amortization- defer non- chang work oper capit invest item invest financ total dividend issuanc retir stock issuanc retir debt financ foreign exchang net chang merck compani inc april
merck end quarter increas revenu impact new tax
legisl billion provision charg anim health
product continu show strong perform remain core growth
driver merck
revenu
quarter
compar
revenu quarter increas compar
pharma revenu increas
compar total revenu anim health care
quarter increas compar
cog quarter
increas
compar
compar
revenu reflect increment revenu due vaccin
sale european countri part sanofi pasteur msd
spmsd vaccin joint ventur termin decemb
total revenu quarter also includ partial
replenish dose gardasil human papillomaviru
vaccin recombin borrow center diseas
control prevent cdc
total revenu compar also reflect favor
impact due time shipment japan prior year
revenu unfavor affect lost sale
certain market relat cyber-attack occur june
cog quarter increas compar
gross margin compar
non-gaap gross margin compar
sg expens quarter declin compar
previou year quarter decreas expens due lower
acquisit divestiture-rel cost
 expens declin compar
declin due lower in-process research develop
ipr impair charg partial off-set higher expens relat
busi develop transact clinic develop spend
invest earli drug develop
result overview
incom expens net incom compar
expens non-gaap incom expens net
incom compar expens
effect incom tax rate compar
non-gaap effect incom tax rate
compar
net loss quarter declin compar
ep compar
non-gaap ep compar
full year total revenu increas compar
full year revenu reflect increment revenu
pharma revenu increas compar
anim health care revenu compar
increas revenu due launch keytruda zepati
bridion well posit perform merck anim health busi
higher revenu pneumovax adempa well anim health
product also contribut revenu growth
merck unabl fulfil order certain product certain market due
cyber-attack unfavor effect revenu
 revenu declin compar
sale increas
compar
decreas revenu due effect gener competit
zetia vytorin cubicin declin product within diversifi brand
includ nasonex dulera inhal aerosol revenu
increas due growth keytruda zepati higher revenu
vaccin due termin spmsd joint ventur higher
revenu anim health product
incom tax rate
compar
incom tax rate
compar
 revenu
declin compar
sale
increas compar
result overview
gross margin compar
increas gross margin due lower acquisit divestiture-rel
cost restructur cost
sg expens increas compar increas
reflect higher administr cost includ cost associ vaccin
busi previous part spmsd vaccin joint ventur
remedi cost relat cyber-attack higher promot expens
relat product launch
 expens decreas compar
declin reflect lower ipr impair charg restructur cost
incom expens net expens compar
expens non-gaap incom expens net
expens compar expens
incom expens net reflect favor impact foreign exchang
gain sale secur
effect tax rate compar
includ unfavor impact provision charg relat
tax legisl non-gaap effect tax rate compar
net incom declin compar
gaap ep compar non-gaap ep
compar
total cash invest includ cash
cash equival short-term invest long-term
recent enact tax legisl improv merck financi
flexibl invest sustain long-term valu creat opportun merck
plan invest year capit project includ
gross margin
compar
increas
gross margin due
lower acquisition-
restructur cost
total cash
invest
cash cash
equival short-
term invest
long-term
segment perform
merck oper two busi segment pharmaceut
pharmaceut pharmaceut product includ therapeut
prevent agent gener sold prescript treatment human
pharma revenu increas compar
pharma revenu increas
compar
increas revenu due signific growth keytruda merck
continu launch keytruda multipl new indic global strong
momentum treatment patient nsclc contribut significantli
keytruda overal growth approv first-
total pharmaceut segment revenu
compar segment intern revenu
compar
primari women health
total revenu zetia market countri outsid unit
state ezetrol vytorin market outsid unit state inegi
atozet market certain countri outsid unit state
adempa declin fy compar
revenu declin due lower volum price zetia
vytorin unit state result gener competit
zetia/vytorin revenu quarter declin
compar zetia/vytorin revenu
compar
pursuant collabor bayer ag bayer merck lead
commerci right adempa countri outsid america
bayer lead right america includ unit state
revenu adempa compar
pharma revenu
increas
compar
increas revenu
due signific growth
keytruda
revenu zetia
vytorin atozet
declin
compar
segment perform
total product revenu compar
total intern revenu compar
total revenu januvia janumet quarter increas
compar total product revenu declin
compar includ favor
effect foreign exchang
total product revenu declin due on-going price pressur
partial off-set continu volum growth global
revenu product januvia janumet
compar total intern revenu
compar
gener medicin women health
total revenu nuvar declin compar
includ favor effect foreign exchang
revenu declin due lower revenu unit state lower
demand europ
total revenu implanon/nexplanon increas
compar increas due higher price
volum growth unit state
total revenu januvia
janumet
quarter increas
compar
total revenu
nuvar declin
compar
includ
favor effect
increas
compar
revenu product nuvar implanon/nexplanon
follistim aq compar total
intern revenu product compar
hospit specialti
zepati revenu quarter increas compar
product revenu increas
compar product revenu increas due
higher sale europ unit state japan follow product
launch intern market
segment perform
total revenu isentress isentress hd declin
compar total product revenu declin
compar
revenu product decreas due lower demand unit
state europ due competit pressur
revenu compar
total intern revenu product compar
total revenu quarter increas compar
total revenu compar
bridion revenu increas compar
product revenu increas
compar increas product revenu
due strong global demand particularli unit state
noxafil revenu increas compar
product revenu increas
compar increas revenu due higher
demand price unit state volum growth europ
invanz revenu quarter increas compar
product revenu increas
compar increas due higher revenu
unit state result higher price partial off-set
lower demand also higher demand brazil
canciduss revenu declin compar
product revenu declin
compar declin product revenu
due gener competit certain european market
total revenu
hd declin
compar
revenu product
bridion increas
compar
revenu product
cancidu declin
compar
compar
segment perform
cubicin revenu declin compar
product revenu declin
compar composit patent
cubicin expir june product revenu declin result
gener competit
revenu product declin
compar total intern revenu
product compar
total revenu quarter declin compar
total revenu compar
remicad revenu declin compar
product revenu declin
compar
simponi revenu increas compar
product revenu increas
compar includ favor effect
foreign exchang increas revenu due higher demand
total oncolog revenu quarter compar
total revenu compar
revenu product keytruda increas
compar product revenu increas
compar increas revenu
due volum growth market particularli unit state europ
japan product continu launch multipl new indic
revenu keytruda emend temodar increas
compar total intern
revenu compar
revenu product
remicad declin
compar
product
revenu declin
compar
revenu product
keytruda increas
compar
segment perform
total revenu singulair nasonex dulera
compar total product revenu
compar
singulair revenu quarter declin compar
product revenu declin
compar product declin due lower
volum japan result gener competit
nasonex revenu quarter declin compar
product revenu declin
compar revenu product declin due
gener competit
dulera revenu quarter declin compar
product revenu declin
compar declin revenu due lower sale
unit state reflect on-going competit price pressur well
revenu product compar
total intern revenu
compar
total revenu cozaar arcoxia fosamax
compar total product revenu
compar
total revenu gardasil/gardasil proquad/m-m-r ii/varivax
pneumovax rotateq zostavax compar
total product revenu
compar
singulair revenu
quarter declin
compar
dulera revenu
quarter declin
compar
total revenu
rotateq
zostavax
compar
segment perform
revenu product gardasil/gardasil increas
compar
product revenu increas compar
increas revenu due higher sale europ result
termin spmsd joint ventur well higher demand asia
proquad/m-m-r ii/varivax revenu quarter compar
product revenu
compar
pneumovax revenu increas compar
product revenu increas
compar increas revenu due
higher demand price unit state well higher sale
europ result termin spmsd joint ventur
rotateq revenu quarter compar
product revenu increas
compar increas revenu due higher
sale europ result termin spmsd joint ventur
zostavax revenu decreas compar
product revenu compar
revenu declin due lower demand
unit state reflect approv competitor vaccin receiv
preferenti recommend acip octob
prevent shingl zostavax
revenu product compar
total intern revenu
compar
pharmaceut sale quarter decreas
y/i compar revenu
compar
revenu product
increas
compar
revenu product
zostavax decreas
compar
sale quarter
decreas
y/i compar
segment perform
other segment includ anim health
anim includ pharmaceut vaccin product prevent
treatment control diseas major farm companion anim
speci anim health sale affect competit frequent
introduct gener product
total revenu quarter increas compar
revenu compar
increas revenu due higher sale companion anim
product larg due growth bravecto line product kill flea
tick dog cat week higher revenu rumin
product swine product poultri product also contribut
merck expand focu oncolog advanc develop
program keytruda therapi receiv key regulatori
approv busi develop transact
decemb fda accept review supplement bla
keytruda treatment adult pediatr patient refractori
pmbcl relaps two prior line therapi
merck announc pivot phase trial investig
keytruda combin pemetrex alimta cisplatin
carboplatin first-lin treatment patient metastat non-
squamou non-smal cell lung cancer nsclc met dual primari
endpoint overal surviv os progression-fre surviv
merck announc pivot phase trial investig
keytruda second-lin treatment patient advanc gastric
gastroesophag junction adenocarcinoma meet primari
endpoint overal surviv patient whose tumor express
total revenu
anim health care
quarter increas
compar
decemb
fda accept review
supplement bla
keytruda
treatment adult
pediatr patient
refractori pmbcl
relaps
two prior line
therapi
merck european organ research treatment cancer
eortc announc phase trial investig
keytruda monotherapi surgic resect high-risk melanoma met
primari endpoint recurrence-fre surviv base interim
analysi follow review independ data monitor
committe result significantli longer recurrence-fre surviv
japanes ministri labor welfar approv keytruda
treatment patient radic unresect urotheli carcinoma
progress cancer chemotherapi
fda approv lynparza use patient germlin brca-mut
metastat breast cancer previous treat
chemotherapi either neoadjuv adjuv metastat
ertugliflozin investig oral inhibitor
review eu investig fixed-dos combin
sitagliptin ipragliflozin review japan
investig pediatr hexaval combin vaccin
ipv-hib-hepb review fda develop
approv commerci joint ventur merck
sanofi
investig rvsv-zebov ebola vaccin candid
studi larg scale phase clinic trial
januari merck announc fda accept review two
nda doravirin nda includ data doravirin once-daili
tablet use combin antiretrovir agent use
doravirin lamivudin tenofovir disoproxil fumar once-daili
fixed-dos combin singl tablet complet regimen
japanes ministri
labor
keytruda
treatment patient
radic
carcinoma
progress cancer
announc fda
accept review two
nda doravirin
lynparza olaparib oral parp inhibitor approv certain
type ovarian breast cancer selumetinib oral potent
select inhibitor mek part mitogen-activ protein kinas
mapk pathway develop multipl cancer type
announc
also known apec
inactiv varicella zoster viru vaccin develop
prevent herp zoster merck complet phase trial autolog
hematopoiet cell transplant patient anoth phase trial patient
solid tumor malign undergo chemotherapi hematolog
select non-narcot orally-administ
agonist develop treatment refractori chronic cough merck
plan initi phase clinic trial first half
februari merck announc stop protocol also
known apec studi phase studi evalu verubecestat mk-
investig small molecul inhibitor beta-sit amyloid
precursor protein cleav enzym peopl prodrom
merck made strateg decis discontinu develop
investig combin regimen
treatment chronic hcv infect
merck announc fda approv steglatro ertugliflozin
tablet oral sodium-glucos cotransport inhibitor fixed-
dose combin steglujan ertugliflozin sitagliptin fixed-dos
combin segluromet ertugliflozin metformin hydrochlorid
help improv glycem control adult type diabet
fda european commiss approv prevymi letermovir once-
daili tablet oral use inject intraven infus indic
prevent cytomegaloviru cmv infect diseas adult cmv-
seroposit recipi allogen hematopoiet stem cell transplant
fda approv isentress raltegravir merck integras inhibitor use
combin antiretrovir agent treatment
newborn patient birth four week age weigh least kg
inhibitor use
combin
antiretrovir agent
treatment
newborn patient
birth four week
age weigh least
tabl show pipelin product develop differ phase merck
phase reviewcanc keytruda advanc solid tumor ovarian prostatebacteri infect relebactam imipenem/cilastatin octob molecular entities/vaccineschron cough keytruda breast octob colorect novemb esophag decemb gastric may eu head neck novemb eu hepatocellular may nasopharyng april renal octob small-cel lung may lynparza pancreat decemb prostat april selumetinib thyroid june mellitu sitagliptin ipragliflozin ertugliflozin ertugliflozin sitagliptin ertugliflozin metformin mellitu keytruda breast octob colorect novemb esophag decemb gastric may eu head neck novemb eu hepatocellular may renal octob small-cel lung may pancreat decemb prostat april thyroid june mellitu sitagliptin ipragliflozin japan ertugliflozin eu ertugliflozin sitagliptin eu ertugliflozin metformin eu hiv infect vaccin march doravirin doravirine/lamivudine/tenofovir disoproxil fumar pneumoconjugatevaccin failur vericiguat septemb hexaval combin vaccin zoster inactiv vzv vaccin decemb supplement file keytruda relaps refractori primari mediastin bcell lymphoma pmbcl broader approv ovarian cancer eu hiv doravirin decemb doravirin lamivudin tenofovir disoproxil fumar june develop collabor develop current hold investig pediatr hexaval combin vaccin develop approv commerci partnership merck sanofi novemb fda issu respect compani work provid addit data request fda merck compani inc april
merck expect revenu includ
posit impact foreign exchang
ep expect non-
ep expect includ neg
impact foreign exchang
non-gaap tax rate expect
non-gaap oper expens expect increas y/i due increas
merck continu bring innov patient physician
expand focu oncolog advanc develop program
keytruda pembrolizumab therapi lynparza olaparib
parp inhibitor co-develop co-commerci astrazeneca
total revenu increas compar
increas due launch keytruda zepati bridion posit
perform merck anim health busi segment
profit grew compar due higher revenu
favor effect product mix
revenu
non-gaap tax rate
expect
continu bring
innov patient
physician
expand focu
gross margin
compar
oper
incom
compar
gross margin compar oper
incom compar roa roe
respect
cash oper activ declin compar
net chang cash merck plan
invest year capit project includ
non- reconcili
non- reconcili
non- reconcili
incom statement
result
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin increas reduc cog compar
revenu growth ttm compar
oper incom compar
ep declin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc april
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale merck compani inc april
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqreturn mrqcapex salescap ex salesfre /sale merck compani inc april
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item merck compani inc april
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang merck compani inc april
price-to-earnings drop averag till averag price-to-earnings average
stdev average stdev
price-to-earnings went averag current
incom statement
result
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form kenneth willi weir mirian robert adam michael juli richard institut holdersholdershar report outvaluevanguard group inc wellington manag compani capit world price row associ northern trust jp morgan top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf incom fund america washington mutual investor vanguard institut fund-institut vanguard specialized-health vanguard/wellington fund ishar fidel merck compani inc april
developmentsfda grant prioriti review merck supplement biolog licens applic sbla keytruda pembrolizumab treatment advanc cervic cancerth food drug administr fda accept new supplement biolog licens applic sbla grant prioriti review keytruda pembrolizumab compani therapi first file accept prioriti review grant therapi cervic cancer regulatori submiss accept fda keytruda eisai co ltd merck enter global strateg oncolog collabor lenvima lenvatinib mesyl eisai co ltd merck agre upon strateg collabor world-wide co-develop co-commerci lenvima lenvatinib mesyl oral avail tyrosin kinas inhibitor discov eisai agreement eisai merck develop commerci lenvima jointli monotherapi combin merck therapi keytruda pembrolizumab lynparza olaparib receiv posit eu chmp opinion platinum-sensit relaps ovarian cancerastrazeneca merck announc committe medicin product human use chmp european medicin agenc adopt posit opinion recommend market author lynparza olaparib tablet mg twice daili use mainten therapi patient platinum-sensit relaps high grade epitheli ovarian fallopian tube primari periton cancer complet respons partial respons platinum-bas chemotherapi lynparza recommend treatment set regardless patient brca mutat statu fda approv lynparza olaparib germlin brca-mut metastat breast cancerth food drug administr fda approv lynparza olaparib use patient deleteri suspect deleteri germlinebrca-mut gbrcam human epiderm growth factor receptor metastat breast cancer previous treat chemotherapi neoadjuv adjuv metastat settingmarch merck compani inc april
incom statement
result
guidanc
non-
per share item
product perform develop
valuat consensu perform
ytd stock perform
vs
price-to-earnings ratio ttm
industri
averag
gross margin ttm
industri
averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc april
consensu view analyst trend stock
growth forecast
lower
 forecast
forward price-to-earnings
lower compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonmrkindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current quarter compar
next quarter
sale growth current
quarter estim
compar next
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr analyst recommend
incom statement
result
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price went januari decemb
stock price went februari trade around
share come high trade level
march share trade around march trade around
stock went februari fell level oct
stock price increas compar went sinc octob
experienc declin sale major brand keytruda bridion zepati
lynparza gain market share global market expect low mid-singl digit growth
revenu maintain rate buy tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
